Cargando…

34. TARGETED THERAPY FOR HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

INTRO: One in three women with HER2-positive breast cancer will develop brain metastases, or intracranial metastatic disease (IMD). Historically, treatment of IMD has been confined to surgery and radiotherapy, with a limited role for chemotherapy. However, recent interest has burgeoned in a role for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erickson, Anders, Ghodrati, Farinaz, Das, Sunit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401393/ http://dx.doi.org/10.1093/noajnl/vdaa073.022

Ejemplares similares

HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders W, et al.
Publicado: (2020)

74. EFFICACY OF HER2-TARGETED THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS
por: Hulsbergen, Alexander, et al.
Publicado: (2020)

04. ASSESSMENT OF EFFICACY AND SAFETY OF OSIMERTINIB FOR PATIENTS WITH INTRACRANIAL METASTATIC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Erickson, Anders, et al.
Publicado: (2020)

SYST-03 INCIDENCE AND SURVIVAL OF PATIENTS WITH INTRACRANIAL METASTATIC DISEASE AND ERBB2-POSITIVE GASTROINTESTINAL CANCERS: A RETROSPECTIVE COHORT STUDY
por: Sherman, Madison, et al.
Publicado: (2022)

THER-01. Targeted therapy and intracranial metastatic disease: a population-based retrospective cohort study
por: Erickson, Anders, et al.
Publicado: (2021)

SYST-05 OPTIMIZING HER2-TARGETED THERAPIES (TT) FOR BREAST CANCER (BC) LEPTOMENINGEAL METASTASES (LM): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Lazaratos, Anna-Maria, et al.
Publicado: (2022)

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020)

OTHR-10. Diverse survival outcomes of HER2+ Breast Cancer Brain Metastases (BrCBM) presenting with isolated brain relapse compared to those with concurrent extracranial disease
por: Noteware, Laura, et al.
Publicado: (2021)

54. tGLI1 IS AN ACTIONABLE THERAPEUTIC TARGET IN BREAST CANCER BRAIN METASTASES
por: Doheny, Daniel, et al.
Publicado: (2020)

BSCI-14. tGLI1 is an actionable therapeutic target in breast cancer brain metastases
por: Doheny, Daniel, et al.
Publicado: (2021)

OTHR-14. An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM)
por: Kennedy, Lucy Boyce, et al.
Publicado: (2021)

BSCI-06 COMPREHENSIVE ANALYSIS OF THE IMMUNOGENOMICS OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES FROM LCCC1419
por: Van Swearingen, Amanda, et al.
Publicado: (2022)

DDRE-34. TARGETING RESISTANCE IN MEDULLOBLASTOMA
por: Chang, Simone, et al.
Publicado: (2021)

Advances in the management of breast cancer brain metastases
por: Sammons, Sarah, et al.
Publicado: (2021)

72. THE COMBINED USE OF STEROIDS AND IMMUNE CHECKPOINT INHIBITORS IN BRAIN METASTASES PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Jessurun, Charissa, et al.
Publicado: (2020)

RADI-10. Is there any benefit for post-operative radiation in brain metastases? A systematic review and meta-analysis of Randomized controlled trials
por: Bolem, Nagarjun, et al.
Publicado: (2021)

32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES
por: Galldiks, Norbert, et al.
Publicado: (2020)

51. BRAIN METASTASES FROM ENDOMETRIAL CARCINOMA: TUMOR GENETIC ALTERATIONS IN A CASE SERIES AND META-ANALYSIS
por: Chapman, Emily K, et al.
Publicado: (2020)

MMAP-11 VOLUMETRIC STUDY OF BRAIN METASTASES IN EGFR-POSITIVE NSCLC TREATED WITH OSIMERTINIB WITH OR WITHOUT CNS-DIRECTED RADIATION THERAPY
por: Ni, Lisa, et al.
Publicado: (2022)

BSCI-05 REPURPOSING PROPOFOL FOR THE TREATMENT OF BRAIN METASTASES
por: Penning, Donald, et al.
Publicado: (2022)

MMAP-10 ADVERSE RADIATION EFFECT AFTER STEREOTACTIC RADIOSURGERY AND IMMUNOTHERAPY/TARGETED THERAPY FOR MELANOMA BRAIN METASTASES
por: Phuong, Christina, et al.
Publicado: (2022)

BSCI-04 TARGETING THE PI3K-MTOR PATHWAY TO TREAT UBE2C-DRIVEN BRAIN METASTASES
por: Paisana, Eunice, et al.
Publicado: (2022)

RADI-06. Gamma knife surgery for brain stem metastases
por: Tan, Choo Heng, et al.
Publicado: (2021)

BSCI-07. Multiomics characterization of brain metastases in multiple histologies identifies enrichment of oxidative phosphorylation as a promising therapeutic target
por: Fukumura, Kazutaka, et al.
Publicado: (2021)

22. COMPARATIVE EFFICACY OF ALK-INHIBITORS IN ALK INHIBITOR-NAIVE ALK+ LUNG CANCER BRAIN METASTASES: A NETWORK META-ANALYSIS
por: Haddad, Philip, et al.
Publicado: (2020)

MET-10 Preliminary report of radiotherapy for brain metastases from breast and kidney using mask system of Leksell Gamma Knife Icon
por: Kawabe, Takuya, et al.
Publicado: (2020)

OTHR-12. The development of machine learning algorithms for the differentiation of glioma and brain metastases – a systematic review
por: Brim, Waverly Rose, et al.
Publicado: (2021)

16. GAMMA KNIFE CLINICAL DOSE PROFILE FOR EXTENSIVE BRAIN METASTASES
por: Bowden, Greg, et al.
Publicado: (2020)

47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES
por: Bassey-Archibong, Blessing, et al.
Publicado: (2020)

TRLS-04. A Nomogram for Predicting Survival in Patients with Brain Metastases
por: Wang, Zhenning, et al.
Publicado: (2021)

MLTI-03. The relevance of the count of brain metastases for treatment and outcome in NSCLC
por: Reinecke, David, et al.
Publicado: (2021)

MLTI-04. The Role of the Outpatient Registered Nurse in the care of Brain Metastases
por: Hernandez, Juliana, et al.
Publicado: (2021)

BSCI-21 COX4I1 EXPRESSION IN BRAIN METASTASES
por: Saad, Mahak, et al.
Publicado: (2022)

33. SYSTEMATIC REVIEW AND META-ANALYSIS OF BREAST CANCER BRAIN METASTASIS AND PRIMARY TUMOR RECEPTOR EXPRESSION DISCORDANCE
por: Kotecha, Rupesh, et al.
Publicado: (2020)

65. INVASIVE HISTOPATHOLOGY DRIVES POOR OUTCOMES IN SURGICALLY RESECTED BRAIN METASTASES
por: Dankner, Matthew, et al.
Publicado: (2020)

RADI-01. Cystic brain metastases managed with reservoir placement and stereotactic radiosurgery
por: Park, David, et al.
Publicado: (2021)

SURG-14. Laser Ablation for Brain Metastases: Risk Factors for Neurologic Complication
por: Pawloski, Jacob, et al.
Publicado: (2021)

BSCI-13. MTH1 expression is upregulated in brain metastases of malignant melanoma
por: Timmer, Marco
Publicado: (2021)

RADI-09. Clinical factors associated with death after radiotherapy for brain metastases
por: Natesan, Divya, et al.
Publicado: (2021)

CLRM-11 CURRENT STATE OF CLINICAL TRIALS FOR PATIENTS WITH MELANOMA BRAIN METASTASES
por: Elghawy, Omar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_59s8vh1vnnarumk9q3d8t11qqp